

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Longitude Venture Partners L.P.</u> (Last) (First) (Middle) <u>C/O LONGITUDE CAPITAL PARTNERS, LLC</u> <u>800 EL CAMINO REAL, SUITE 220</u> (Street) <u>MENLO PARK CA 94025</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>CORCEPT THERAPEUTICS INC [CORT]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>11/22/2016</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	11/22/2016		S		9,411	D	\$9.3297 ⁽¹⁾	13,802,702	D ⁽²⁾	
Common Stock	11/22/2016		S		189	D	\$9.3297 ⁽¹⁾	180,641	I	By LCA ⁽³⁾
Common Stock	11/23/2016		S		12,352	D	\$9.3038 ⁽⁴⁾	13,790,350	D ⁽²⁾	
Common Stock	11/23/2016		S		248	D	\$9.3038 ⁽⁴⁾	180,393	I	By LCA ⁽³⁾
Common Stock	11/25/2016		S		14,451	D	\$9.3869 ⁽⁵⁾	13,775,899	D ⁽²⁾	
Common Stock	11/25/2016		S		290	D	\$9.3869 ⁽⁵⁾	180,103	I	By LCA ⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person*
Longitude Venture Partners L.P.

 (Last) (First) (Middle)
C/O LONGITUDE CAPITAL PARTNERS, LLC
800 EL CAMINO REAL, SUITE 220

 (Street)
MENLO PARK CA 94025

 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Longitude Capital Partners, LLC

 (Last) (First) (Middle)
800 EL CAMINO REAL SUITE 220

 (Street)

MENLO PARK CA 94024

(City) (State) (Zip)

1. Name and Address of Reporting Person *

Tammenoms Bakker Juliet

(Last) (First) (Middle)

800 EL CAMINO REAL SUITE 220

(Street)

MENLO PARK CA 94024

(City) (State) (Zip)

1. Name and Address of Reporting Person *

Longitude Capital Associates, L.P.

(Last) (First) (Middle)

800 EL CAMINO REAL SUITE 220

(Street)

MENLO PARK CA 94024

(City) (State) (Zip)

Explanation of Responses:

1. Reflects sales of common stock executed in multiple transactions at prices ranging from \$9.300 to \$9.3600. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected.
2. Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Venture Partners, L.P. ("LVP"). This report is filed jointly by LVP, Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP, and Juliet Tammenoms Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LVP. LVP may also be deemed a director by virtue of its right to nominate a representative to serve on the Issuer's Board of Directors. Patrick G. Enright currently serves as LVP's representative on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein.
3. Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Capital Associates, L.P. ("LCA"). This report is jointly filed by LCA, Longitude Capital, the sole general partner of LCA, and Ms. Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LCA. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein.
4. Reflects sales of common stock executed in multiple transactions at prices ranging from \$9.3000 to \$9.3400. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected.
5. Reflects sales of common stock executed in multiple transactions at prices ranging from \$9.3000 to \$9.4600. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected.

Remarks:

/s/ Juliet Tammenoms Bakker,
as managing member of
Longitude Capital Partners, 11/25/2016
LLC, as general partner of
Longitude Venture Partners,
L.P.

/s/ Juliet Tammenoms Bakker,
as managing member of
Longitude Capital Partners, 11/25/2016
LLC

/s/ Juliet Tammenoms Bakker 11/25/2016

/s/ Juliet Tammenoms Bakker,
as managing member of
Longitude Capital Partners, 11/25/2016
LLC, as general partner of
Longitude Capital Associates,
L.P.

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.